作者
Kensuke Kubota,Takaya Oguchi,Nao Fujimori,Kenta Yamada,Itaru Naitoh,Yoshinobu Okabe,Eisuke Iwasaki,Atsushi Masamune,Tsukasa Ikeura,Terumi Kamisawa,Dai Inoue,Teru Kumagi,Takeshi Ogura,Yuzo Kodama,Akio Katanuma,Kenji Hirano,Kazuo Inui,Hiroyuki Isayama,Junichi Sakagami,Takayoshi Nishino,Atsushi Kanno,Yusuke Kurita,Kazuichi Okazaki,Seiji Nakamura
摘要
We attempted to determine the indications and limitations of steroid therapy as the first-line therapy in patients with autoimmune pancreatitis (AIP) with cyst formation (ACF).This Japanese multicenter survey was conducted to examine the merits/demerits of steroid treatment as the initial therapy for ACF.Data of a total of 115 patients with ACF were analyzed. Complete remission was achieved in 86% (86/100) of patients who had received steroid treatment, but only 33.3% (5/15) of patients who had not received steroids. Relapse after the remission (n = 86) occurred in 7.6% (6/86) of patients who had received steroid therapy, but 40% (2/5) of patients who had not received steroid therapy. Multivariate analysis identified adoption of the wait and watch approach without steroid treatment (odds ratio = 0.126, P < .001) as a significant and independent negative predictor of remission of ACF. As for predictors of relapse, the presence of varix (odds ratio = 5.83, P = .036) was identified as an independent risk factor.Steroid therapy plays an important role as first-line therapy in AIP patients with pancreatic cyst formation, however, varix formation, besides the diameter of the cyst(s), is a risk factor for refractoriness to steroid therapy.